Search Results - "Leleux, Jardin A"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma by Pradhan, Pallab, Qin, Hong, Leleux, Jardin A, Gwak, Dongho, Sakamaki, Ippei, Kwak, Larry W, Roy, Krishnendu

    Published in Biomaterials (01-07-2014)
    “…Abstract Success of an immunotherapy for cancer often depends on the critical balance of T helper 1 (Th1) and T helper 2 (Th2) responses driven by antigen…”
    Get full text
    Journal Article
  2. 2

    Biophysical Attributes of CpG Presentation Control TLR9 Signaling to Differentially Polarize Systemic Immune Responses by Leleux, Jardin A., Pradhan, Pallab, Roy, Krishnendu

    Published in Cell reports (Cambridge) (17-01-2017)
    “…It is currently unknown whether and how mammalian pathogen recognition receptors (PRRs) respond to biophysical patterns of pathogen-associated molecular danger…”
    Get full text
    Journal Article
  3. 3

    Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory by Leleux, Jardin A, Albershardt, Tina C, Reeves, Rebecca, James, Reice, Krull, Jordan, Parsons, Andrea J, Ter Meulen, Jan, Berglund, Peter

    Published in PloS one (02-12-2021)
    “…Systemic interleukin-12 (IL12) anti-tumor therapy is highly potent but has had limited utility in the clinic due to severe toxicity. Here, we present two…”
    Get full text
    Journal Article
  4. 4

    Surface-Presentation of CpG and Protein–Antigen on Pathogen-Like Polymer Particles Generate Strong Prophylactic and Therapeutic Antitumor Protection by Dawson, Eileen, Leleux, Jardin A, Pradhan, Pallab, Roy, Krishnendu

    Published in ACS biomaterials science & engineering (13-02-2017)
    “…Despite significant efforts, development of clinically relevant prophylactic and therapeutic cancer vaccines has proven challenging. Cancer-associated…”
    Get full text
    Journal Article
  5. 5

    ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities by Leleux, Jardin A., Albershardt, Tina C., Parsons, Andrea J., ter Meulen, Jan, Berglund, Peter

    Published in Vaccine (22-09-2020)
    “…Therapeutic cancer vaccines must induce high levels of tumor-specific cytotoxic CD8 T cells to be effective. We show here that tumor-antigen specific effector…”
    Get full text
    Journal Article
  6. 6

    Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist by Leleux, Jardin A, Albershardt, Tina C, Reeves, Rebecca, James, Reice, Krull, Jordan, Parsons, Andrea J, ter Meulen, Jan, Berglund, Peter

    Published in PloS one (02-12-2021)
    “…Systemic interleukin-12 (IL12) anti-tumor therapy is highly potent but has had limited utility in the clinic due to severe toxicity. Here, we present two…”
    Get full text
    Journal Article